Clinical Trial Update: Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating IMC-A12 (Cixutumumab) in metastatic prostate cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• IMC-A12 (cixutumumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED | Results posted: 2018-07-19